Publications by authors named "T F Tvedskov"

Materials And Methods: This study included patients registered in the national Danish Breast Cancer Group (DBCG) database between 2001 and 2015, with locoregional LNM as well as a bilateral negative mammography, ultrasonography, and physical examination of the breasts. Overall survival (OS) and invasive disease-free survival (IDFS) were compared by treatment groups, ALND + RT (axillary lymph node dissection and radiotherapy) or ALND + MAST ± RT (axillary lymph node dissection, mastectomy with or without radiotherapy).

Results: In total, 56 patients were included in the study, of which 37 were treated by ALND + RT, 16 by ALND + MAST ± RT, and the remaining three patients receiving different treatments.

View Article and Find Full Text PDF

Background: Increasing life expectancy increases breast cancer (BC) rates in elderly, where better health allows for improved tolerance of treatments. We assessed trends in BC incidence of tumor subtypes for women with focus on the elderly.

Methods: Changes in BC incidence in women by age from 2012 to 2021 were assessed using data from the Nordic countries.

View Article and Find Full Text PDF

Accurate initial staging of patients with breast cancer is essential for planning optimal treatment strategies. However, currently, no imaging modality is able to detect lymph node metastases preoperatively with sufficient reliability; therefore, the N status depends on the sentinel node procedure for ~ 70% of patients. In a prospective clinical trial of breast cancer patients, we compared head-to-head uPAR-PET/CT with current standard-of-care, ultrasound (US) and fine needle biopsy (FNB) as staging methods.

View Article and Find Full Text PDF
Article Synopsis
  • * In premenopausal patients, a high proportion (83.6%) received chemotherapy regardless of the axillary method used, but postmenopausal rates varied significantly by region, notably low in Denmark (36.0%).
  • * No significant difference in 5-year recurrence-free survival was found between the two axillary treatment groups for postmenopausal patients, suggesting a need for better strategies to avoid under-treatment while minimizing risks.
View Article and Find Full Text PDF

Background: De-escalation of adjuvant treatment in patients with T1abN0 breast cancer is discussed internationally. Identification of new prognostic factors in these patients may assist this de-escalation. The PAM50 signature and tumor inflammation signature (TIS), Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) signatures are possible prognostic factors for recurrence.

View Article and Find Full Text PDF